Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Allergan |
---|---|
Information provided by: | Allergan |
ClinicalTrials.gov Identifier: | NCT00440141 |
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%
Condition | Intervention | Phase |
---|---|---|
Glaucoma Ocular Hypertension |
Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Enrollment: | 40 |
Study Start Date: | July 2006 |
Study Completion Date: | March 2007 |
Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops
latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
|
2: Active Comparator |
Drug: latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Allergan, Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | MA-AP01 |
Study First Received: | February 22, 2007 |
Last Updated: | December 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00440141 |
Health Authority: | United States: Institutional Review Board |
Pseudoephedrine Brinzolamide Eye Diseases Vascular Diseases Tetrahydrozoline Latanoprost Naphazoline Oxymetazoline |
Guaifenesin Glaucoma Phenylephrine Ephedrine Phenylpropanolamine Ocular Hypertension Hypertension Brimonidine |
Respiratory System Agents Neurotransmitter Agents Adrenergic alpha-Agonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Sympathomimetics Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents |
Pharmacologic Actions Adrenergic Agonists Nasal Decongestants Carbonic Anhydrase Inhibitors Autonomic Agents Therapeutic Uses Vasoconstrictor Agents Cardiovascular Diseases Peripheral Nervous System Agents |